Next Article in Journal
Coelenterazine-Dependent Luciferases as a Powerful Analytical Tool for Research and Biomedical Applications
Next Article in Special Issue
Advances, Perspectives and Potential Engineering Strategies of Light-Gated Phosphodiesterases for Optogenetic Applications
Previous Article in Journal
The Diverse Roles of TAO Kinases in Health and Diseases
Previous Article in Special Issue
Multi-Compartment, Early Disruption of cGMP and cAMP Signalling in Cardiac Myocytes from the mdx Model of Duchenne Muscular Dystrophy
Open AccessReview

Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases

Department of Pharmacology and Toxicology, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(20), 7462; https://doi.org/10.3390/ijms21207462
Received: 2 September 2020 / Revised: 7 October 2020 / Accepted: 8 October 2020 / Published: 10 October 2020
(This article belongs to the Special Issue Role of Phosphodiesterase in Biology and Pathology)
Phosphodiesterases (PDEs) are the principal superfamily of enzymes responsible for degrading the secondary messengers 3′,5′-cyclic nucleotides cAMP and cGMP. Their refined subcellular localization and substrate specificity contribute to finely regulate cAMP/cGMP gradients in various cellular microdomains. Redistribution of multiple signal compartmentalization components is often perceived under pathological conditions. Thereby PDEs have long been pursued as therapeutic targets in diverse disease conditions including neurological, metabolic, cancer and autoimmune disorders in addition to numerous cardiovascular diseases (CVDs). PDE2 is a unique member of the broad family of PDEs. In addition to its capability to hydrolyze both cAMP and cGMP, PDE2 is the sole isoform that may be allosterically activated by cGMP increasing its cAMP hydrolyzing activity. Within the cardiovascular system, PDE2 serves as an integral regulator for the crosstalk between cAMP/cGMP pathways and thereby may couple chronically adverse augmented cAMP signaling with cardioprotective cGMP signaling. This review provides a comprehensive overview of PDE2 regulatory functions in multiple cellular components within the cardiovascular system and also within various subcellular microdomains. Implications for PDE2- mediated crosstalk mechanisms in diverse cardiovascular pathologies are discussed highlighting the prospective use of PDE2 as a potential therapeutic target in cardiovascular disorders. View Full-Text
Keywords: PDE2; cAMP/cGMP crosstalk; natriuretic peptides; NO signaling; heart failure; arrhythmia; inflammation; cardiovascular disease PDE2; cAMP/cGMP crosstalk; natriuretic peptides; NO signaling; heart failure; arrhythmia; inflammation; cardiovascular disease
Show Figures

Figure 1

MDPI and ACS Style

Sadek, M.S.; Cachorro, E.; El-Armouche, A.; Kämmerer, S. Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases. Int. J. Mol. Sci. 2020, 21, 7462. https://doi.org/10.3390/ijms21207462

AMA Style

Sadek MS, Cachorro E, El-Armouche A, Kämmerer S. Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases. International Journal of Molecular Sciences. 2020; 21(20):7462. https://doi.org/10.3390/ijms21207462

Chicago/Turabian Style

Sadek, Mirna S.; Cachorro, Eleder; El-Armouche, Ali; Kämmerer, Susanne. 2020. "Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases" Int. J. Mol. Sci. 21, no. 20: 7462. https://doi.org/10.3390/ijms21207462

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop